Format

Send to

Choose Destination
Eur Respir J. 2015 Jun;45(6):1624-31. doi: 10.1183/09031936.00199614. Epub 2015 Jan 22.

Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia.

Author information

1
Second Division, Dept of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
2
Second Division, Dept of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. fujisawa@hama-med.ac.jp.
3
Dept of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
4
Dept of Internal Medicine, Enshu Hospital, Hamamatsu, Japan.
5
Dept of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
6
Dept of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
7
Dept of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
8
Dept of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
9
Dept of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
10
Dept of Respiratory Medicine, Iwata City Hospital, Iwata, Japan.
11
Dept of Respiratory Medicine, Tenryu Hospital, National Hospital Organization, Hamamatsu, Japan.
12
Dept of Internal Medicine, Hamamatsu Toyooka Hospital, Hamamatsu, Japan.

Abstract

In patients with chronic eosinophilic pneumonia (CEP), dramatic improvements are seen in response to corticosteroid therapy; however, relapse is common after treatment has ceased. The optimal duration of corticosteroid therapy remains unclear. In a randomised, open-label, parallel group study, eligible patients with CEP received oral prednisolone for either 3 months (3-month group) or 6 months (6-month group), followed by 2 years observation. All patients were treated with an initial dose of prednisolone of 0.5 mg·kg(-1)·day(-1), which was then tapered and discontinued at either 3 or 6 months. The primary end-point was relapse during the follow-up period. In the final analysis, there were 23 patients in the 3-month group and 21 patients in the 6-month group. All patients showed a good response to prednisolone treatment. There were 12 (52.1%) relapses in the 3-month group and 13 (61.9%) relapses in the 6-month group. No significant difference was found in the cumulative rate of relapse (p=0.56). All relapse cases showed improvement upon resumption of prednisolone treatment. No difference was observed in the rate of relapse between the 3- and 6-month prednisolone treatment groups for patients with CEP.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00632554.

PMID:
25614171
DOI:
10.1183/09031936.00199614
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center